Logo

Rosetta Green Hits Milestone in Algae-Modification Initiative

Apr 26, 2012
Premium

Rosetta Green last week announced that it has successfully completed an experiment producing biologically active human growth hormone from algae.

The work was conducted as part of a collaborative effort funded by the European Commission focused on the use of genetic modifications to improve algae for industrial applications (GSN 7/28/2011).

Through the initiative, Rosetta Green is identifying miRNAs that could be used to develop algae that can produce therapeutic human proteins and growth hormone.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
miRNA
Rosetta Green
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.